Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 117Carcinoma, Transitional Cell 39Testicular Neoplasms 23Urethral Neoplasms 18Testicular Germ Cell Tumor 14Ovarian Neoplasms 13Teratoma 12Prostatic Neoplasms 11Endodermal Sinus Tumor 11Seminoma 10Neoplasms 10Carcinoma, Embryonal 9Ureteral Neoplasms 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Renal Cell 7Stomach Neoplasms 6Penile Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Breast Neoplasms 6Urologic Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Urothelial Cancer 4Lung Neoplasms 4Central Nervous System Neoplasms 4Wilms Tumor 3Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1berzosertib 1aldesleukin 1Platinum 1Immunoglobulin G 1Gemcitabine 1Cyclophosphamide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Bladder Urothelial Carcinoma × Cisplatin × Genitourinary × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡